Pharmacy Focus : Episode 69

What to Know About the Approval of Lecanemab-irmb

News
Podcast

Nikhil Palekar discusses the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.

In an interview with Pharmacy Times, Nikhil Palekar, MD, director of the Stony Brook Center of Excellence for Alzheimer Disease, director of the Stony Brook Division for Geriatric Psychiatry, and director of the Stony Brook Alzheimer Disease clinical trials program, discussed the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.

Although the treatment is not a cure and cannot reverse early Alzheimer disease, Palekar said it could give patients crucial more time to join other clinical trials investigating potential treatments.

Related Videos
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
Pharmacy Times Public Health Matters Podcast (logo)
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Therapy session -- Image credit: pressmaster | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.